Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced a significant manufacturing milestone for its lead drug candidate ONC010, a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor designed to target solid tumors. The company successfully produced and isolated approximately 952 grams of the B4 precursor component through its collaboration with Dalton Pharma Services, advancing kilogram-scale manufacturing capabilities.
The achievement supports the company’s integrated development strategy, enabling future formulation development, Good Manufacturing Practice (GMP) production, and planned clinical studies. By establishing a scalable production process, Onco-Innovations is positioning itself to meet clinical supply demands as the program progresses. The B4 precursor is a critical element of ONC010, which aims to disrupt cancer cell DNA repair mechanisms.
In a separate announcement, Onco-Innovations engaged InvestorBrandNetwork (IBN) to provide market awareness, corporate communications, and digital media services through September 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 and intends to apply an unused US$80,000 balance from a prior market awareness engagement toward the consideration.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company holds an exclusive worldwide license to patented technology targeting solid tumors. This manufacturing milestone underscores its commitment to advancing novel therapies from research to clinical application.
For more information, visit https://oncoinnovations.com/ and the full press release at https://ibn.fm/BbWHd.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Onco-Innovations Achieves Kilogram-Scale Manufacturing Milestone for ONC010 Cancer Program.